21 August 2018
Visiongain’ has launched a new pharma report Needle-Free Delivery Technology Market 2018-2028: Jet Injector Technology, Competing Technologies, Novel Needle Technology, Inhaler Technology, Patch Technology.
The growth of the needle-free delivery technology is driven by unmet needs such as the high incidence of needlestick injuries and the need for a more efficient method of delivering mass vaccinations in rural areas. The market will also be boosted by biological drugs and the rapid growth in emerging market patient populations with access to novel medical devices.
In this report, needle-free drug delivery technologies encompass two types of injector technologies — jet injector technology and the competing needle-free technologies (novel needle technology, inhaler technology and transdermal patch technology). Novel needle technologies include both pen needles and microneedles.
The lead analyst of the report commented "It is anticipated that the future will see continued growth in biologics-drug delivery partnering deals. Visiongain predicts that manufacturers will look to novel self-administration devices as a key way to compete as the biosimilar market continues to rise over the next few years. Moreover, the diabetes biologic drug market represents a major driver for the needle-free delivery technology market."
Leading companies featured in the report include 3M, Antares Pharma, Becton Dickinson, BioJect Medical Technologies, PharmaJet, Zogenix.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.